Universal Nasal Vaccine Shows Promise Against COVID-19, Flu, and More

A new intranasal vaccine developed by researchers at Stanford Medicine is demonstrating broad-spectrum protection against a range of respiratory viruses, bacteria, and even allergens in mice. The experimental vaccine, dubbed GLA-3M-052-LS+OVA, could potentially replace multiple annual vaccinations and offer a crucial defense against future pandemics.

How Does the Universal Vaccine Work?

Unlike traditional vaccines that target specific pathogens by mimicking their unique components, this novel approach focuses on bolstering the body’s innate immune defenses. The vaccine mimics signals used by immune cells during an infection, integrating both the innate and adaptive immune systems to create a sustained, broad-spectrum response. Stanford Medicine researchers explain that this strategy enhances the innate immune response, which is typically short-lived, allowing it to persist for an extended period.

The vaccine directly stimulates innate defenses in the lungs by mimicking T cell signals. It also contains ovalbumin, an egg protein that acts as a harmless antigen, recruiting T cells to maintain the immune response for weeks or months.

Study Results in Mice

Published in the journal Science on February 19, 2026, the study revealed that vaccinated mice were protected against SARS-CoV-2 and other coronaviruses, as well as common hospital-acquired infections like Staphylococcus aureus and Acinetobacter baumannii, and even house dust mites, a common allergen. ScienceDaily reports that mice receiving three doses of the vaccine remained protected for at least three months.

Unvaccinated mice exposed to respiratory viruses experienced severe weight loss, lung inflammation, and high mortality rates. The research suggests a “double whammy” effect: the prolonged innate response reduced viral load in the lungs up to 700 times, while the adaptive response cleared any remaining virus. Protection against bacteria was observed for approximately three months, and allergic reactions were blocked by maintaining clear airways in exposed animals.

What’s Next?

Researchers are planning to initiate clinical trials in humans with a Phase I study to evaluate the vaccine’s safety. Bali Pulendran, PhD, the senior author of the study, estimates that two doses of the nasal spray could be sufficient. U.S. News & World Report indicates that, with adequate funding, a universal respiratory vaccine could be available within five to seven years.

Key Takeaways

• A new intranasal vaccine, GLA-3M-052-LS+OVA, shows broad protection against respiratory viruses, bacteria, and allergens in mice.
• The vaccine works by stimulating the innate immune system, providing longer-lasting protection than traditional vaccines.
• Study results demonstrate protection against SARS-CoV-2, Staphylococcus aureus, Acinetobacter baumannii, and house dust mites.
• Clinical trials in humans are planned to evaluate the vaccine’s safety and efficacy.